Low molecular weight nucleoside gelator: A novel approach for protein and peptide aggregation inhibition
Protein and peptide based therapeutics have become one of the most rapidly growing class of therapeutics that have potential to treat human disease. However, their inherent instability limits their application, which in turn minimises their therapeutic potential. Among all the physical and chemical...
| Main Author: | |
|---|---|
| Format: | Thesis (University of Nottingham only) |
| Language: | English |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://eprints.nottingham.ac.uk/56035/ |
| _version_ | 1848799260007464960 |
|---|---|
| author | Johnson, Litty |
| author_facet | Johnson, Litty |
| author_sort | Johnson, Litty |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Protein and peptide based therapeutics have become one of the most rapidly growing class of therapeutics that have potential to treat human disease. However, their inherent instability limits their application, which in turn minimises their therapeutic potential. Among all the physical and chemical instabilities, protein aggregation has become the major important cause of concern in the biopharmaceutical industry. Several additives are currently employed to prevent this. However, these additives possess several drawbacks such as their ability to denature proteins. Thus, there is a need to develop a novel method for the prevention of aggregation that could extend the shelf life of these biotherapeutics.
Low molecular weight nucleoside gelators have been widely used as a candidate for the delivery of biologics due to their excellent biocompatibility. However, their influence on the inhibition of protein aggregation has not been studied. Herein, we are reporting the ability of the nucleoside gelator, N4-octanoyl-2ʹ-deoxycytidine to inhibit protein aggregation.
Using turbidimetric, spectroscopic and microscopy methods, we have demonstrated that inhibition of protein aggregation is dependent on gelator concentration. Moreover the model proteins were found to be functionally active in the hydrogel system. All our results revealed that this gelator exhibited the ability to suppress aggregation of proteins with a broad range of isoelectric points. Thus, the 2ʹ deoxycytidine based hydrogel has potential in tackling one of the most important challenges in the formulation of biologics i.e.protein aggregation. |
| first_indexed | 2025-11-14T20:32:50Z |
| format | Thesis (University of Nottingham only) |
| id | nottingham-56035 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-14T20:32:50Z |
| publishDate | 2019 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-560352025-02-28T14:23:14Z https://eprints.nottingham.ac.uk/56035/ Low molecular weight nucleoside gelator: A novel approach for protein and peptide aggregation inhibition Johnson, Litty Protein and peptide based therapeutics have become one of the most rapidly growing class of therapeutics that have potential to treat human disease. However, their inherent instability limits their application, which in turn minimises their therapeutic potential. Among all the physical and chemical instabilities, protein aggregation has become the major important cause of concern in the biopharmaceutical industry. Several additives are currently employed to prevent this. However, these additives possess several drawbacks such as their ability to denature proteins. Thus, there is a need to develop a novel method for the prevention of aggregation that could extend the shelf life of these biotherapeutics. Low molecular weight nucleoside gelators have been widely used as a candidate for the delivery of biologics due to their excellent biocompatibility. However, their influence on the inhibition of protein aggregation has not been studied. Herein, we are reporting the ability of the nucleoside gelator, N4-octanoyl-2ʹ-deoxycytidine to inhibit protein aggregation. Using turbidimetric, spectroscopic and microscopy methods, we have demonstrated that inhibition of protein aggregation is dependent on gelator concentration. Moreover the model proteins were found to be functionally active in the hydrogel system. All our results revealed that this gelator exhibited the ability to suppress aggregation of proteins with a broad range of isoelectric points. Thus, the 2ʹ deoxycytidine based hydrogel has potential in tackling one of the most important challenges in the formulation of biologics i.e.protein aggregation. 2019-03-15 Thesis (University of Nottingham only) NonPeerReviewed application/pdf en arr https://eprints.nottingham.ac.uk/56035/1/Final%20Thesis%20%28e%20thesis%20submission%29.pdf Johnson, Litty (2019) Low molecular weight nucleoside gelator: A novel approach for protein and peptide aggregation inhibition. MRes thesis, University of Nottingham. gel nucleoside gelator protein aggregation inhibition protein therapeutics |
| spellingShingle | gel nucleoside gelator protein aggregation inhibition protein therapeutics Johnson, Litty Low molecular weight nucleoside gelator: A novel approach for protein and peptide aggregation inhibition |
| title | Low molecular weight nucleoside gelator: A novel approach for protein and peptide aggregation inhibition |
| title_full | Low molecular weight nucleoside gelator: A novel approach for protein and peptide aggregation inhibition |
| title_fullStr | Low molecular weight nucleoside gelator: A novel approach for protein and peptide aggregation inhibition |
| title_full_unstemmed | Low molecular weight nucleoside gelator: A novel approach for protein and peptide aggregation inhibition |
| title_short | Low molecular weight nucleoside gelator: A novel approach for protein and peptide aggregation inhibition |
| title_sort | low molecular weight nucleoside gelator: a novel approach for protein and peptide aggregation inhibition |
| topic | gel nucleoside gelator protein aggregation inhibition protein therapeutics |
| url | https://eprints.nottingham.ac.uk/56035/ |